Original Research
Published on 26 Sep 2022
Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
in Gastrointestinal Cancers: Colorectal Cancer
- 4,146 views
- 12 citations